Literature DB >> 34895031

Immunosurveillance, interferon, and autophagic networking in cancer: the PRKCI-ULK2 paradigm.

Jorge Moscat1, Ana Maria Cuervo2, Maria T Diaz-Meco1.   

Abstract

The mechanisms controlling immunosurveillance and immunoevasion often operate simultaneously to the triggering of the oncogenic signaling that results in tumor initiation. The resolution of the balance between anti-cancer immune responses and pro-tumorigenic pathways determines if a tumor cell survives and can remodel the microenvironment to reinforce immunosuppression or is eliminated by the immune system. Cancer cells must endure a toxic and metabolically challenging milieu. In its various forms, autophagy provides a way for transformed cells to survive by promoting catabolism and detoxification. Mounting evidence suggests that the boundaries between cancer immunity and mitogenic and metabolic programs are diffuse, with the same molecules likely serving several diverse roles in immunity and metabolism during tumor initiation and progression. Our recent data provide mechanistic detail and functional relevance of a new paradigm whereby the same signaling elements control immunity and autophagy in cancer.

Entities:  

Keywords:  Atypical PKC; ULK2; autophagy; immunosurveillance; interferon

Mesh:

Substances:

Year:  2021        PMID: 34895031      PMCID: PMC8865275          DOI: 10.1080/15548627.2021.1991192

Source DB:  PubMed          Journal:  Autophagy        ISSN: 1554-8627            Impact factor:   13.391


  1 in total

1.  PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis.

Authors:  Juan F Linares; Xiao Zhang; Anxo Martinez-Ordoñez; Angeles Duran; Hiroto Kinoshita; Hiroaki Kasashima; Naoko Nakanishi; Yuki Nakanishi; Ryan Carelli; Luca Cappelli; Esperanza Arias; Masakazu Yashiro; Masaichi Ohira; Sanjay Patel; Giorgio Inghirami; Massimo Loda; Ana Maria Cuervo; Maria T Diaz-Meco; Jorge Moscat
Journal:  Mol Cell       Date:  2021-09-23       Impact factor: 17.970

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.